Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging.
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis / Baroncini, Damiano; Simone, Marta; Iaffaldano, Pietro; Brescia Morra, Vincenzo; Lanzillo, Roberta; Filippi, Massimo; Romeo, Marzia; Patti, Francesco; Chisari, Clara Grazia; Cocco, Eleonora; Fenu, Giuseppe; Salemi, Giuseppe; Ragonese, Paolo; Inglese, Matilde; Cellerino, Maria; Margari, Lucia; Comi, Giancarlo; Zaffaroni, Mauro; Ghezzi, Angelo. - In: JAMA NEUROLOGY. - ISSN 2168-6149. - 78:6(2021), pp. 726-735. [10.1001/jamaneurol.2021.1008]
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis
Filippi, Massimo;Comi, Giancarlo;
2021-01-01
Abstract
Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging.| File | Dimensione | Formato | |
|---|---|---|---|
|
JAMA Neurol 78_726.pdf
solo gestori archivio
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Tutti i diritti riservati
Dimensione
576.25 kB
Formato
Adobe PDF
|
576.25 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
